Could a Custom-Tailored therapy beat standard talk therapy for tough depression?
NCT ID NCT07380451
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new type of talk therapy that is personalized for each person's emotional, relationship, and self-image struggles. It is for adults with depression that also involves personality problems or past trauma. 150 people in Chile's public health system will get either this modular therapy or usual one-on-one therapy. The goal is to see if the personalized approach leads to more people feeling better and staying well.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Modular Intervention for Depression Therapy (MIND Therapy) - a personalized psychotherapy
- What this could lead to
- If successful, this could provide a more effective, personalized therapy option for depression complicated by personality issues or trauma, especially in public health settings.
- What could go wrong
- This is a small pilot study (150 people) in one country's public system, so results may not apply broadly. The therapy is complex and may not outperform usual care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
May 2026
An estimate. Start dates often move.
- Expected to finish
-
Feb 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Current diagnosis of major depressive disorder, defined as: * Positive diagnosis on the MINI diagnostic interview, and * PHQ-9 score greater than 10 * Evidence of personality dysfunction, defined as a score above the cutoff on the Level of Personality Functioning Scale-Brief Form (LPFS-BF 2.0). * History of moderate to severe early life adversity, defined as elevated scores on at least one scale of the Childhood Trauma Questionnaire (CTQ), and/or clinically significant alterations in self-organization. * Presence of at least one elevated domain of alteration of self-organization, including emotion regulation difficulties, interpersonal sensitivity, and/or interpersonal functioning problems, as assessed by standardized self-report measures (DERS, A-RSQ, OQ-45-IR). * Receiving care at a participating public community mental health center in Chile. * Ownership of a smartphone (Android or iOS) with internet access and an active data plan. * Ability to provide written informed consent. Exclusion Criteria: * Acute suicide risk requiring immediate intensive intervention, as assessed by the MINI. * Any severe psychiatric disorder other than major depressive disorder that is the primary clinical diagnosis, including: * Schizophrenia or other psychotic disorders * Bipolar I disorder * Severe substance use disorder, active within the past 6 months. * Diagnosis of post-traumatic stress disorder (PTSD) meeting full diagnostic criteria, as assessed by standardized instruments (ITEM and ITQ). * Meeting diagnostic criteria for: * Antisocial personality disorder (two or more criteria), or * Borderline personality disorder with more than three diagnostic criteria * Severe medical, cognitive, or psychosocial condition that would interfere with participation in weekly psychotherapy. * Concurrent participation in another active psychotherapy or initiation/change of psychotropic medication during the study period, except for: * Stable antidepressant treatment * Medications prescribed for sleep * Benzodiazepines used only on an as-needed (PRN) basis. * Inability to comply with study procedures or assessments.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Major depression are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
4 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CDT CASR
RECRUITINGSantiago, Chile
-
COSAM La Bandera
ACTIVE_NOT_RECRUITINGSantiago, Chile
-
COSAM La Granja
RECRUITINGSantiago, Chile
-
COSAM La Pintana
RECRUITINGSantiago, Chile
-
COSAM Rinconada
RECRUITINGSantiago, Chile
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an amino acid shift brain chemistry in depression?
- Zapping two brain regions may restore pleasure in depression
- What can patients who tried both brain-stimulation treatments teach us?
- Can virtual reality lift teen depression?
- Can a brain stimulation cocktail supercharge depression treatment?
- Brain wave clues: could inflammation markers forecast ECT outcomes?